Identification of new alleles and the determination of alleles and genotypes frequencies at the CYP2D6 gene in emiratis

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Qumsieh, Rula Y ^a   Ali, Bassam R ^a   Abdulrazzaq, Yousef M ^a   Osman, Ossama ^a   Akawi, Nadia A ^a   Bastaki, Salim M A ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; GENOMIC DNA; CYTOCHROME P450 2D6;

ARTICLE; CONTROLLED STUDY; CYP2D6 GENE; DNA SEQUENCE; EMIRATIS; ENDOGENOUS DEPRESSION; ETHNIC GROUP; GENE; GENE DOSAGE; GENE DUPLICATION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MENTAL PATIENT; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED ARAB EMIRATES; WILD TYPE; GENETICS;

CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENOTYPE; HUMANS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UNITED ARAB EMIRATES;

EID: 84055216947     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028943     Document Type: Article

References (31)

1. Bernard S, Neville KA, Nguyen AT, Flockhart DA, (2006) Interethnic Differences in Genetic Polymorphisms of CYP2D6 in the U.S. Population: Clinical Implications Oncologist 11: 126-135.
2. Ma MK, Woo MH, McLeod HL, (2002) Genetic basis of drug metabolism. Am J Health Syst Pharm 59: 2061-2069.
3. Dahl ML, Bertilsson L, Chang M, Roh HK, Aden Abdi Y, et al. (1995) Genetic contribution to interethnic variations in drug oxidation. In: Alván G, Balant LP, Bechtel PR, Boobis AR, Gram LF, Paintaud G, Pithan K, editors. COST B1 Conference on Variability and Specificity in Drug Metabolism pp. 111-124 (European Commission, Luxembourg).
4. Eichelbaum M, Gross AS, (1990) The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 46: 377-394.
5. Kalow W, (2005) A pharmacogeneticist's look at drug effects and the drug development process: an overview. Expert Opin Pharmacother 6 (8): 1299-1303.
6. Dahl M-L, Bertilsson L, (1993) Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics 3: 61-70.
7. Cascorbi I, (2003) Pharmacogenetics of cytochrome p4502D6: genetic background and clinical implication. Eur J Clin Invest 33 (suppl 2): 17-22.
8. Masimirembwa C, Persson I, Bertilsson L, Hasler J, Ingelman-Sundberg M, (1996) A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity. Br J Clin Pharmacol 42: 713-719.
9. Daly AK, Armstrong M, Monkman SC, Idle ME, Idle JR, (1991) Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome P4502D6) phenotypes. Pharmacogenetics 1: 33-41.
10. Broly F, Gaedigk A, Heim M, Eichelbaum M, Morike K, et al. (1991) Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol 10: 545-58.
11. Hosono N, Kato M, Kiyotani K, Mushiroda T, Takata S, et al. (2009) CYP2D6 Genotyping for Functional-Gene Dosage Analysis by Allele Copy Number Detection. Clinical Chemistry 55: 1546-1554.
12. Ingelman-Sundberg M, (2005) Genetic polymorphism of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenetics J 5: 6-13.
13. Evans WE, Relling MV, (2004) Moving towards individualized medicine with pharmacogenomics. Nature 429: 464-468.
14. Bertilsson L, (1995) Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29: 192-209.
15. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F, et al. (1994) Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46 (3): 452-459.
16. Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C, (2009) Novel variants of major drug-metabolising genes in diverse African population and their predicted functional effects. Hum Genomics 3 (2): 169-190.
17. McLellan RA, Oscarson M, Seidegard J, Evans DAP, Ingelman-Sundberg M, (1996) genotype analysis of cytochrome P450D26 in a Saudi Arabian population. XIth International Symposium on microsomes and drug oxidation. Los Angeles, CA; P-205.
18. Kawanishi C, Lundgren S, Agren H, Bertilsson L, (2004) Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol 59: 803-807.
19. Toscano C, Klein K, Blievernicht J, Schaeffeler E, Saussele T, et al. (2006) Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenet Genomics 16: 755-766.
20. Bozina N, Granic P, Lalic Z, Tramisak I, Lovric M, et al. (2003) Genetic Polymorphisms of Cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian Population. Croatian Med J 44: 425-428.
21. McLellan RA, Oscarson M, Seidegård J, Evans DA, Ingelman-Sundberg M, (1997) Frequent occurrence of CYP2D6 gene duplication in Saudi Arabians. Pharmacogenetic 7: 187-191.
22. Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, et al. (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193-202.
23. Sachse C, Brockmoller J, Hildebrand M, Muller K, Roots I, (1998) Correctness of prediction of the CYP2D6 phenotype confirmed by genotyping 47 intermediate and poor metabolizes of debrisoquine. Pharmacogenetics 8: 181-185.
24. Zanger UM, Hofmann MH, (2008) Polymorphic cytochrome P450 CYP2B6 and CYP2D∧: recent advances on single nucleotide polymorphisms affecting slicing. Acta Chimica Slovenica 55: 38-44.
25. Sistonen J, Sajantila A, Oscar L, Corander J, Barbujani G, et al. (2007) CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 17: 93-101.
26. De Leon J, Armstrong SC, Cozza KL, (2006) Clinical guidelines for psychiatrics for the use of pharmacogenetic testing for CYP450 2D6 and CYP450 2C19. Psychosomatics 47: 75-85.
27. Kirchheiner J, Nickchen K, Bauer M, Wong ML, Licinio J, et al. (2004) Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 9: 442-473.
28. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, et al. (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278: 441-446.
29. Zanger UM, Raimundo S, Eichelbaum M, (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, and biochemistry. Naunyn Schmiedebergs Arch Pharmacol 369: 23-37.
30. Kouhi H, Hamzeiy H, Barar J, Asadi M, Omidi Y, (2009) Frequency of Five Important CYP2D6 Alleles within an Iranian Population (Eastern Azerbaijan). Genet Test Mol Biomarkers 13: 665-670.
31. Britzi M, Bialer M, Arcavi L, Schacbari A, Kapitulnik T, et al. (2000) Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. Ther Drug Monit 22: 510-516.